Awakn Life Sciences Strengthens Executive Leadership Team Post published:November 30, 2021 Post category:Press Release
Awakn Life Sciences Signs MOU with NHS (Devon Partnership NHS Trust) and University of Exeter with a View of Increasing Access to Psychedelic-Assisted Psychotherapy in the UK Post published:November 16, 2021 Post category:Press Release
MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE’s Digital Therapeutics Platform Post published:October 28, 2021 Post category:Press Release
Awakn Life Sciences Identifies New Chemical Series via Its Drug Discovery Program Post published:October 28, 2021 Post category:Press Release
Awakn Life Sciences Acquires Exclusive Rights to MDMA Research from Imperial College London Post published:September 23, 2021 Post category:Press Release
Awakn Life Sciences to Acquire Leading Ketamine-Assisted Psychotherapy Clinic in Norway Post published:September 16, 2021 Post category:Press Release
Awakn Life Sciences Reports Second Quarter 2021 Financial Results and Business Highlights Post published:September 15, 2021 Post category:Press Release
Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction Led by Professor Celia Morgan Post published:August 24, 2021 Post category:Press Release
Awakn Life Sciences Begins Trading on the OTCQB(R) Venture Market Under the Symbol ‘AWKNF’ on August 12th Post published:August 12, 2021 Post category:Press Release
Awakn Life Sciences Announces Its Second Location in the UK for “Awakn Clinics London,” Providing Treatment to the Largest City in the UK Post published:August 4, 2021 Post category:Press Release